Simple blood test aims to catch cancers early in genetically prone patients
NCT ID NCT06450171
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a blood test called GRAIL Galleri that looks for signs of many different cancers at once. It is being offered to 1000 people who have a high risk of cancer due to inherited genetic conditions. The goal is to see if the test can find cancers early, when they might be easier to treat.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GRAIL Galleri blood test
- What this could lead to
- If successful, this could show that a simple blood test helps catch multiple cancers earlier in people with high genetic risk, potentially improving treatment options.
- What could go wrong
- This is an early-stage study without a control group, so it cannot prove the test saves lives. False positives or unnecessary procedures are possible risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER PREDISPOSITION SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.